Page last updated: 2024-11-08

3-o-methyl-alpha-methyldopamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-O-methyl-alpha-methyldopamine: metabolite of p-methoxyamphetamine; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID197139
CHEMBL ID1347
CHEBI ID173516
SCHEMBL ID9434236
MeSH IDM0097972

Synonyms (30)

Synonym
CHEBI:173516
3-o-methyl-a-methyldopamine
13026-44-3
3-o-methyl-alpha-methyldopamine
3-methoxy-4-hydroxyphenylisopropylamine
brn 2804928
phenol, 4-(2-aminopropyl)-2-methoxy-
4-(2-aminopropyl)-2-methoxyphenol
NCI60_001388
AKOS000152652
SCHEMBL9434236
CHEMBL1347 ,
bdbm50404648
uw5v6g007j ,
3-13-00-02250 (beilstein handbook reference)
unii-uw5v6g007j
AKOS017269172
3-0-methyl-.alpha.-methyldopamine, (+/-)-
4-hydroxy-3-methoxy-.alpha.-methylphenethylamine
dl-4-hydroxy-3-methoxy-.alpha.-methylphenethylamine
3-0-methyl-.alpha.-methyldopamine, (rs)-
4-hydroxy-3-methoxyamphetamine
DTXSID30926648
E79481
(+/-)-3-0-methyl-alpha-methyldopamine
Q27291302
mfcd01707832
SY271547
EN300-2595236
PD047710

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These findings suggest that neither of MDA's major metabolites mediate its toxic effects on 5-HT neurons and that either a minor metabolite is responsible or that alternate mechanisms are involved."( Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons.
McCann, UD; Ricaurte, GA, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd3.54810.00042.47358.5114AID5800
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID5799Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities.
AID5800Antagonistic against 5-hydroxytryptamine 2B receptor1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's5 (41.67)18.2507
2000's4 (33.33)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.12 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]